March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
FDA Grants Orphan Drug Designation to Umbralisib for Patients with Follicular LymphomaMarch 10th 2020
The FDA granted orphan drug designation to umbralisib based on results from the phase IIb UNITY-NHL trial cohort of patients with follicular lymphoma who have received at least 2 prior lines of therapy, including an anti-CD20 monoclonal antibody and an alkylating agent.
FDA Grants Priority Review to Tafasitamab/Lenalidomide Combination for DLBCLMarch 2nd 2020
The FDA granted priority review to a biologics license application for tafasitamab in combination with lenalidomide for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Rituximab with BEAM Conditioning Prior to Auto-HCT for DLBCL not RecommendedFebruary 27th 2020
This recommendation was based on an analysis of patients with diffuse large B-cell lymphoma undergoing auto-HCT in which the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes.
FDA Grants Priority Review to Tazemetostat for Relapsed/Refractory Follicular LymphomaFebruary 14th 2020
The submission was primarily based on updated phase II efficacy and safety data for tazemetostat for patients with relapsed or refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy.
Early Findings Show Promise of CAR NK-Cell Therapy in Leukemia, LymphomaFebruary 8th 2020
Patients with either relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with CAR NK cells had a response without the development of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
Survey Illustrates Current Status of PD-1/PD-L1 Inhibitors in ChinaFebruary 7th 2020
Researchers indicated that a lack of understanding of the mechanism and efficacy of PD-1/PD-L1 inhibitors is the major barrier for prescription of these inhibitors in Chinese tumor treatment-related departments.
Phase I Trial Aims to Evaluate Cobomarsen in Certain Hematologic MalignanciesFebruary 4th 2020
The phase I trial is evaluating cobomarsen in cancers where the disease process appears to be correlated with an increase in miR-155 levels, including adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.
Samantha Jaglowski, MD, MPH, on Next Steps Regarding Tisagenlecleucel for Patients with DLBCLJanuary 9th 2020
The associate professor at The Ohio State University Comprehensive Cancer Center explained the goals for the future of the CAR T-cell therapy data in patients with DLBCL.
Brentuximab Vedotin with Re-induction Chemotherapy Effective, Well Tolerated in AMLJanuary 3rd 2020
A phase I study showed brentuximab vedotin combined with a standard chemotherapy regimen of mitoxantrone, etoposide, and cytarabine may be safe and well tolerated in patients with relapsed/refractory acute myeloid leukemia.
Diego Villa, MD, FRCPC, Discusses Bendamustine and Rituximab as Induction Therapy in MCLJanuary 3rd 2020
Diego Villa, MD, FRCPC, elaborated on the progress made with bendamustine and rituximab as induction therapy for transplant eligible and ineligible patients with mantle cell lymphoma.
Simon Rule, MD, PhD, on Long-Term Outcomes with Ibrutinib Versus Prior Treatment RegimensJanuary 2nd 2020
The expert hematologist from Plymouth University Medical Center discussed the long-term outcomes of patients receiving ibrutinib for mantle cell lymphoma at the ASH Annual Meeting and Exposition.
Samantha Jaglowski, MD, MPH, Discusses Implications of Tisagenlecleucel for Patients with DLBCLDecember 16th 2019
The associate professor at The Ohio State University Comprehensive Cancer Center discussed the implications of her analysis of the CAR T-cell therapy tisagenlecleucel for patients with diffuse large B-cell lymphoma at the ASH Annual Meeting & Exposition.
Andre H. Goy, MD, MS, Discusses Extending Survival for Patients with DLBCLDecember 13th 2019
Andre H. Goy, MD, MS, from Hackensack University Medical Center, discussed ways to address the extension of survival for patients with DLBCL who achieved a complete remission at the ASH Annual Meeting & Exposition.
Matthew S. Davids, MD, MMSc, Discusses Study of Duvalisib in Combination with VenetoclaxDecember 10th 2019
Matthew S. Davids, MD, MMSc, discussed his phase I/II study of duvalisib combined with venetoclax for patients with relapsed/refractory CLL and SLL at the ASH Annual Meeting & Exposition.